循环肿瘤细胞用于肝细胞癌精准动态监测的临床应用进展

肝癌电子杂志 ›› 2024, Vol. 11 ›› Issue (1): 21-24.

循环肿瘤细胞用于肝细胞癌精准动态监测的临床应用进展

黄小准¹, 王付尊², 谢云亮¹, 冉义洪¹, 徐林¹, 黄璋侃¹, 殷鑫¹, 毕新宇³, 车旭^1,*

1.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院肝胆外科,广东深圳 518116;
2.深圳市人民医院儿科,广东深圳 518001;
3.国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肝胆外科,北京 100021

收稿日期:2022-12-30 出版日期:2024-03-31 发布日期:2024-05-08
通讯作者: ^*车旭,E-mail：drchexu@126.com
基金资助:
深圳市“医疗卫生三名工程”基金项目（SZSM202011010）; 深圳市高水平医院建设专项经费; 中国医学科学院肿瘤医院深圳医院院内科研课题（E010322004,SZ2020MS011）

Clinical application progress of circulating tumor cells for accurate dynamic monitoring of hepatocellular carcinoma

Huang Xiaozhun¹, Wang Fuzun², Xie Yunliang¹, Ran Yihong¹, Xu Lin¹, Huang Zhangkan¹, Yin Xin¹, Bi Xinyu³, Che Xu^1,*

1. Department of Hepatobiliary Surgery, National Cancer Center/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, Guangdong, China;
2. Department of Pediatrics, Shenzhen People's Hospital, Shenzhen 518001, Guangdong, China;
3. Department of Hepatobiliary Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Received:2022-12-30 Online:2024-03-31 Published:2024-05-08
Contact: ^*Che Xu, E-mail: drchexu@126.com

摘要/Abstract

摘要： 肝细胞癌（hepatocellular carcinoma,HCC）是最常见的恶性肿瘤之一,也是癌症相关死亡的主要原因。目前没有理想的生物标志物可以对接受治疗的HCC患者进行早期诊断和肿瘤监测。循环肿瘤细胞（circulating tumor cell,CTC）已成为在非侵入性环境中进行诊断和监测不同肿瘤治疗反应的有用工具,在HCC患者精准医疗应用方面具有巨大潜力。本文对CTC在指导HCC手术方式、切缘及介入治疗和系统药物治疗等精准动态监测应用中的研究进展进行综述。

关键词: 肝细胞癌, 循环肿瘤细胞, 微血管侵犯, 解剖性切除, 非解剖性切除

Abstract: Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and a major cause of cancer-related death worldwide. There is no ideal biomarker allowing early diagnosis of HCC and tumor surveillance in patients receiving therapy. Circulating tumor cells (CTC) have become a useful tool for diagnosing and monitoring therapeutic responses of different tumors in a non-invasive setting, and have great potential for precision medicine delivery in HCC patients. Based on existing clinical application evidence, this review will discuss the application and research progress of CTC in guiding surgical methods, resection margins, interventional therapy and systematic therapy, and other accurate dynamic monitoring.

Key words: Hepatocellular carcinoma, Circulating tumor cell, Microvascular invasion, Anatomical resection, Non-anatomical resection

黄小准, 王付尊, 谢云亮, 冉义洪, 徐林, 黄璋侃, 殷鑫, 毕新宇, 车旭. 循环肿瘤细胞用于肝细胞癌精准动态监测的临床应用进展[J]. 肝癌电子杂志, 2024, 11(1): 21-24.

Huang Xiaozhun, Wang Fuzun, Xie Yunliang, Ran Yihong, Xu Lin, Huang Zhangkan, Yin Xin, Bi Xinyu, Che Xu. Clinical application progress of circulating tumor cells for accurate dynamic monitoring of hepatocellular carcinoma[J]. Electronic Journal of Liver Tumor, 2024, 11(1): 21-24.

参考文献

[1] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012[J]. Int J Cancer, 2015, 136(5): E359-E386.
[2] BRUIX J, SHERMAN M.Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3): 1020-1022.
[3] TABRIZIAN P, JIBARA G, SHRAGER B, et al.Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis[J]. Ann Surg, 2015, 261(5): 947-955.
[4] YE Q, LING S, ZHENG S, et al.Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA[J]. Mol Cancer, 2019, 18(1): 114.
[5] SUN Y F, GUO W, XU Y, et al.Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma[J]. Clin Cancer Res, 2018, 24(3): 547-559.
[6] LEE H M, JOH J W, SEO S R, et al.Cell-surface major vault protein promotes cancer progression through harboring mesenchymal and intermediate circulating tumor cells in hepatocellular carcinomas[J]. Sci Rep, 2017, 7(1): 13201.
[7] SUO Y, XIE C, ZHU X, et al.Proportion of circulating tumor cell clusters increases during cancer metastasis[J]. Cytometry A, 2017, 91(3): 250-253.
[8] RODRíGUEZ-PERáLVAREZ M, LUONG T V, ANDREANA L, et al. A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability[J]. Ann Surg Oncol, 2013, 20(1): 325-339.
[9] JOHNSON P J.The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma[J]. Clin Liver Dis, 2001, 5(1): 145-159.
[10] ÖZDEMIR F, BASKIRAN A.The Importance of AFP in Liver Transplantation for HCC[J]. J Gastrointest Cancer, 20YAMASHITA Y, TSUIJITA E, TAKEISHI K, et al. Predictors for microinvasion of small hepatocellular carcinoma ≤2 cm[J]. Ann Surg Oncol, 2012, 19(6): 2027-2034.
[11] SHIRABE K, TOSHIMA T, KIMURA K, et al.New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma[J]. Liver Int, 2014, 34(6): 937-941.
[12] RENZULLI M, BROCCHI S, CUCCHETTI A, et al.Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma?[J]. Radiology, 2016, 279(2): 432-442.
[13] POTé N, CAUCHY F, ALBUQUERQUE M, et al.Performance of PIVKA-Ⅱ for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion[J]. J Hepatol, 2015, 62(4): 848-854.
[14] YAMASHITA Y I, IMAI K, YUSA T, et al.Microvascular invasion of single small hepatocellular carcinoma ≤3 cm: Predictors and optimal treatments[J]. Ann Gastroenterol Surg, 2018, 2(3): 197-203.
[15] DU M, CHEN L, ZHAO J, et al.Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma[J]. BMC Cancer, 2014, 14: 38.
[16] ZHOU J, WANG Z, QIU S J, et al.Surgical treatment for early hepatocellular carcinoma: comparison of resection and liver transplantation[J]. J Cancer Res Clin Oncol, 2010, 136(9): 1453-1460.
[17] YAMANAKA N, OKAMOTO E, FUJIHARA S, et al.Do the tumor cells of hepatocellular carcinomas dislodge into the portal venous stream during hepatic resection?[J]. Cancer, 1992, 70(9): 2263-2267.
[18] YU J J, XIAO W, DONG S L, et al.Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma[J]. BMC Cancer, 2018, 18(1): 835.
[19] HA Y, KIM T H, SHIM J E, et al.Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: a prospective study[J]. Hepatol Int, 2019, 13(6): 726-735.
[20] SUN Y F, XU Y, YANG X R, et al.Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection[J]. Hepatology, 2013, 57(4): 1458-1468.
[21] CHEN Z, LIN X, CHEN C, et al.Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation[J]. Ann Transl Med, 2020, 8(17): 1067.
[22] SUN Y F, WANG P X, CHENG J W, et al.Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection[J]. Cancer Cytopathol, 2020, 128(10): 733-745.
[23] ZHOU K Q, SUN Y F, CHENG J W, et al.Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma[J]. EBioMedicine, 2020, 62: 103107.
[24] YU JJ, SHU C, YANG H Y, et al.The Presence of Circulating Tumor Cell Cluster Characterizes an Aggressive Hepatocellular Carcinoma Subtype[J]. Front Oncol, 2021, 11: 734564.
[25] FAN J L, YANG Y F, YUAN C H, et al.Circulating Tumor Cells for Predicting the Prognostic of Patients with Hepatocellular Carcinoma: A Meta Analysis[J]. Cell Physiol Biochem, 2015, 37(2): 629-640.
[26] SHEN J, WANG W S, ZHU X L, et al.High Epithelial Cell Adhesion Molecule-Positive Circulating Tumor Cell Count Predicts Poor Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization[J]. J Vasc Interv Radiol, 2018, 29(12): 1678-1684.
[27] HE Y Z, HE K, HUANG R Q, et al.A clinical scoring system for predicting tumor recurrence after percutaneous radiofrequency ablation for 3 cm or less hepatocellular carcinoma[J]. Sci Rep, 2021, 11(1): 8275.
[28] ZHANG Q, XIA F, GAO H, et al.Circulating Tumor Cells as an Indicator of Treatment Options for Hepatocellular Carcinoma Less Than or Equal to 3 cm in Size: A Multi-Center, Retrospective Study[J]. Front Surg, 2022, 9: 895426.
[29] CHEN Z, WANG T, CHEN C, et al.Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma[J]. J Oncol, 2021: 7776389.
[30] HUANG X, XU L, MA T, et al.Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study[J]. Front Oncol, 2021, 11: 751159.
[31] RAU K M, LIU C T, HSIAO Y C, et al.Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response[J]. J Clin Med, 2020, 9(1): 188.
[32] TELLEZ-GABRIEL M, COCHONNEAU D, CADé M, et al.Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine[J]. Cancers (Basel), 2018, 11(1): 19.
[33] KLAMETH L, RATH B, HOCHMAIER M, et al.Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance[J]. Sci Rep, 2017, 7(1): 5337.
[34] HU C L, ZHANG Y J, ZHANG X F, et al.3D Culture of Circulating Tumor Cells for Evaluating Early Recurrence and Metastasis in Patients with Hepatocellular Carcinoma[J]. Onco Targets Ther, 2021, 14: 2673-2688.
[35] ZHANG Y, ZHANG X, ZHANG J, et al.Microfluidic chip for isolation of viable circulating tumor cells of hepatocellular carcinoma for their culture and drug sensitivity assay[J]. Cancer Biol Ther, 2016, 17(11): 1177-1187.
[36] PAILLER E, FAUGEROUX V, OULHEN M, et al.Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer[J]. Clin Cancer Res, 2019, 25(22): 6671-6682.
[37] LOHR J G, KIM S, GOULD J, et al. Genetic interrogation of circulating multiple myeloma cells at single-cell resolution[J]. Sci Transl Med, 2016, 8(363): 363ra147.
[38] D'AVOLA D, VILLACORTA-MARTIN C, MARTINS-FILHO S N, et al. High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma[J]. Sci Rep, 2018, 8(1): 11570.